Table 6.
HOMA-IR segmented subgroup analysis
| Non-adjusted | Adjust I | Adjust II | P for interaction | |
|---|---|---|---|---|
| HOMA-IR < 3.59 | ||||
| Age dichotomous | 0.4039 | |||
| Low | 0.73 (0.55, 0.99) 0.0398 | 0.73 (0.54, 0.98) 0.0339 | 0.81 (0.59, 1.10) 0.1727 | |
| High | 0.75 (0.63, 0.89) 0.0012 | 0.74 (0.62, 0.88) 0.0008 | 0.94 (0.77, 1.14) 0.5309 | |
| Gender | 0.7908 | |||
| Male | 0.79 (0.66, 0.93) 0.0055 | 0.72 (0.61, 0.86) 0.0002 | 0.88 (0.72, 1.06) 0.1758 | |
| Female | 0.91 (0.69, 1.19) 0.4804 | 0.87 (0.66, 1.13) 0.2932 | 0.92 (0.68, 1.24) 0.5745 | |
| Diabetics | 0.6544 | |||
| Yes | 0.82 (0.71, 0.95) 0.0089 | 0.76 (0.65, 0.88) 0.0002 | 0.88 (0.74, 1.04) 0.1424 | |
| No | 1.10 (0.46, 2.59) 0.8329 | 0.95 (0.37, 2.48) 0.9211 | 1.09 (0.45, 2.65) 0.8545 | |
| Cancer | 0.297 | |||
| Yes | 0.65 (0.49, 0.86) 0.0027 | 0.63 (0.47, 0.85) 0.0024 | 0.77 (0.55, 1.06) 0.1065 | |
| No | 0.87 (0.73, 1.04) 0.1230 | 0.81 (0.68, 0.95) 0.0115 | 0.93 (0.77, 1.12) 0.4529 | |
| Hypoglycemic drugs or insulin Users | 0.8085 | |||
| Yes | 0.86 (0.73, 1.01) 0.0583 | 0.73 (0.62, 0.86) 0.0002 | 0.88 (0.73, 1.05) 0.1642 | |
| No | 0.73 (0.50, 1.07) 0.1105 | 0.81 (0.56, 1.18) 0.2788 | 0.93 (0.63, 1.37) 0.7047 | |
| Lipid-lowering drug users | 0.96 | |||
| Yes | 0.83 (0.72, 0.97) 0.0162 | 0.76 (0.66, 0.88) 0.0004 | 0.89 (0.75, 1.05) 0.1637 | |
| No | 0.85 (0.41, 1.77) 0.6620 | 0.77 (0.36, 1.65) 0.5061 | 0.90 (0.42, 1.95) 0.7988 | |
| HOMA-IR > 3.59 | ||||
| Age dichotomous | 0.2771 | |||
| Low | 1.01 (0.97, 1.05) 0.5769 | 1.01 (0.98, 1.05) 0.4820 | 1.00 (0.96, 1.05) 0.8460 | |
| High | 1.03 (1.00, 1.06) 0.0873 | 1.04 (1.01, 1.07) 0.0094 | 1.03 (1.00, 1.07) 0.0657 | |
| Gender | 0.05 | |||
| Male | 0.99 (0.96, 1.03) 0.7300 | 1.02 (0.99, 1.06) 0.2589 | 1.00 (0.97, 1.04) 0.9058 | |
| Female | 1.05 (1.01, 1.08) 0.0053 | 1.05 (1.02, 1.09) 0.0038 | 1.06 (1.02, 1.10) 0.0040 | |
| Diabetics | 0.7656 | |||
| Yes | 1.02 (0.99, 1.04) 0.1842 | 1.03 (1.01, 1.06) 0.0053 | 1.03 (1.00, 1.05) 0.0565 | |
| No | 0.99 (0.67, 1.44) 0.9381 | 1.01 (0.67, 1.54) 0.9530 | 1.10 (0.70, 1.73) 0.6737 | |
| Cancer | 0.0349 | |||
| Yes | 1.09 (1.04, 1.15) 0.0010 | 1.12 (1.05, 1.18) 0.0002 | 1.10 (1.03, 1.17) 0.0043 | |
| No | 1.01 (0.98, 1.04) 0.5390 | 1.02 (0.99, 1.05) 0.1266 | 1.01 (0.98, 1.04) 0.3709 | |
| Hypoglycemic drugs or insulin Users | 0.0716 | |||
| Yes | 1.01 (0.99, 1.04) 0.2559 | 1.03 (1.01, 1.06) 0.0109 | 1.02 (1.00, 1.05) 0.0977 | |
| No | 1.09 (0.96, 1.24) 0.1717 | 1.17 (1.03, 1.32) 0.0131 | 1.17 (1.03, 1.33) 0.0189 | |
| Lipid-lowering drug users | 0.3338 | |||
| Yes | 1.01 (0.99, 1.04) 0.2313 | 1.03 (1.01, 1.06) 0.0095 | 1.02 (1.00, 1.05) 0.0741 | |
| No | 1.09 (0.96, 1.23) 0.1837 | 1.11 (0.98, 1.27) 0.1089 | 1.12 (0.95, 1.32) 0.1699 | |
hazard ratio(HR), 95% confidence interval(CI),and P-value. Adjust I: Age, sex, race, diabetes, and cancer. Adjust II: Age, sex, race, diabetes, cancer, and variables obtained by using the two-way effect change method. Variables used as stratification criteria were not adjusted